{"title":"Sanofi Augments its Biosurgery Unit with Pluromed Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i3.1705","DOIUrl":null,"url":null,"abstract":"Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"51 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i3.1705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
